MCID: CYC007
MIFTS: 37

Cyclic Thrombocytopenia malady

Categories: Rare diseases, Blood diseases

Aliases & Classifications for Cyclic Thrombocytopenia

Aliases & Descriptions for Cyclic Thrombocytopenia:

Name: Cyclic Thrombocytopenia 50
Thrombocytopenia, Cyclic 52 69
Thrombocytopenia Cyclic 50

Characteristics:

HPO:

32
cyclic thrombocytopenia:
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Cyclic Thrombocytopenia

MalaCards based summary : Cyclic Thrombocytopenia, also known as thrombocytopenia, cyclic, is related to thrombocytopenia and severe nonproliferative diabetic retinopathy, and has symptoms including abnormal bleeding, thrombocytopenia and neutropenia. An important gene associated with Cyclic Thrombocytopenia is GP1BA (Glycoprotein Ib Platelet Alpha Subunit), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Cisplatin and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include t cells and testes.

Related Diseases for Cyclic Thrombocytopenia

Diseases related to Cyclic Thrombocytopenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 48)
id Related Disease Score Top Affiliating Genes
1 thrombocytopenia 10.4
2 severe nonproliferative diabetic retinopathy 10.1 GP1BA THPO
3 thrombocytopenia, congenital amegakaryocytic 10.1 IL3 THPO
4 immunodeficiency 20 10.1 GP1BA THPO
5 cerebellar hypoplasia and mental retardation with or without quadrupedal locomotion 1 10.1 IL3 THPO
6 choledochal cyst 10.1 CSF2 IL3
7 acute panmyelosis with myelofibrosis 10.1 CSF2 IL7
8 febrile seizures, familial, 2 10.1 CSF2 IL3
9 mental retardation, autosomal dominant 37 10.1 CSF2 IL3
10 pericoronitis 10.1 IL3 KITLG
11 scleroderma, familial progressive 10.1 CSF2 IL3
12 necrotizing gastritis 10.1 CSF2 IL3
13 immunodeficiency 21 10.1 GP1BA THPO
14 grix blankenship peterson syndrome 10.1 CSF2 IL3
15 bulbospinal polio 10.0 KITLG THPO
16 childhood malignant mesenchymoma 10.0 CSF2 IL3
17 ocular hyperemia 10.0 GP1BA THPO
18 haemonchiasis 10.0 GP1BA THPO
19 blood coagulation disease 9.9 CSF2 THPO
20 birth defects 9.9 CSF2 IL3
21 intestinal impaction 9.9 IL3 KITLG THPO
22 erythrocytosis, somatic 9.9 IL3 KITLG THPO
23 prostatic cyst 9.9 IL11 THPO
24 dentinogenesis imperfecta 9.9 IL11 THPO
25 dic in newborn 9.9 CSF2 IL3 KITLG
26 myeloproliferative neoplasm 9.9 GP1BA THPO
27 granulomatous hepatitis 9.9 CSF2 IL3 THPO
28 sinusitis 9.9 CSF2 IL3 KITLG
29 acute dacryoadenitis 9.9 CSF2 IL3 KITLG
30 peroxisome biogenesis disorder 7a 9.9 CSF2 IL3 KITLG
31 pharc syndrome 9.9 CSF2 IL11
32 thrombocytosis 9.8
33 neuronal ceroid-lipofuscinoses 9.8 IL11 IL3 THPO
34 basilar artery insufficiency 9.8 IL11 IL3 THPO
35 middle cerebral artery infarction 9.7 CSF2 IL3 KITLG THPO
36 actinobacillosis 9.7 CSF2 IL3 KITLG THPO
37 hemophagocytic lymphohistiocytosis 9.7 CSF2 IL3 KITLG THPO
38 drug-induced hepatitis 9.7 CSF2 IL3 KITLG THPO
39 cranioectodermal dysplasia 1 9.7 CSF2 IL3 KITLG THPO
40 tracheal disease 9.7 GP1BA IL11 IL3 THPO
41 common variable immunodeficiency 9.6
42 purpura 9.6
43 polycythemia 9.6
44 nemaline myopathy 2, autosomal recessive 9.5 CSF2 IL11 IL3 KITLG
45 osteoarthritis 9.4 CSF2 IL11 IL3 KITLG THPO
46 hyperparathyroidism, neonatal 9.4 CSF2 IL11 IL3 KITLG THPO
47 leukemia, acute myeloid 9.4 CSF2 IL11 IL3 KITLG THPO
48 cytokine receptor deficiency 9.1 CSF2 GP1BA IL11 IL3 IL7 KITLG

Graphical network of the top 20 diseases related to Cyclic Thrombocytopenia:



Diseases related to Cyclic Thrombocytopenia

Symptoms & Phenotypes for Cyclic Thrombocytopenia

Human phenotypes related to Cyclic Thrombocytopenia:

32
id Description HPO Frequency HPO Source Accession
1 abnormal bleeding 32 HP:0001892
2 thrombocytopenia 32 HP:0001873
3 neutropenia 32 HP:0001875

Drugs & Therapeutics for Cyclic Thrombocytopenia

Drugs for Cyclic Thrombocytopenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 177)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
2
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
3
Gemcitabine Approved Phase 4,Phase 2,Phase 1 95058-81-4 60750
4
Oprelvekin Approved, Investigational Phase 4,Phase 3,Phase 2 145941-26-0
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
6
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
7
Vidarabine Approved Phase 4,Phase 3,Phase 2 24356-66-9 32326 21704
8
Oxaliplatin Approved, Investigational Phase 4 61825-94-3 5310940 9887054 6857599, 9887054 43805
9
Fluorouracil Approved Phase 4,Phase 3,Phase 2 51-21-8 3385
10
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2 58-05-9 54575, 6560146 143
11
Caffeic acid Experimental Phase 4,Phase 3 331-39-5 1549111
12 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
14 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
15 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
16 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
17 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Phase 1 1177-87-3
18 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
19
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1
20 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
21 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
22 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
23 Dexamethasone 21-phosphate Phase 4,Phase 3,Phase 2,Phase 1
24 Hormones Phase 4,Phase 3,Phase 2,Phase 1
25 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
26 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
27 Protective Agents Phase 4,Phase 3
28 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1
29 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
30 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1
31 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Antioxidants Phase 4,Phase 3
34
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
35
Idarubicin Approved Phase 3,Phase 2 58957-92-9 42890
36
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
37
rituximab Approved Phase 2, Phase 3, Phase 1 174722-31-7 10201696
38
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
39
Azacitidine Approved, Investigational Phase 3,Phase 2,Phase 1 320-67-2 9444
40
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
41
Doxorubicin Approved, Investigational Phase 3,Phase 1,Phase 2 23214-92-8 31703
42
Vincristine Approved, Investigational Phase 2, Phase 3, Phase 1 2068-78-2, 57-22-7 5978
43
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
44
Melphalan Approved Phase 3,Phase 1,Phase 2 148-82-3 4053 460612
45
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
46
Chlorambucil Approved Phase 3,Phase 2 305-03-3 2708
47
Succinylcholine Approved Phase 3,Phase 1 306-40-1 5314
48
Ifosfamide Approved Phase 3,Phase 1,Phase 2 3778-73-2 3690
49
Mechlorethamine Approved Phase 3,Phase 1,Phase 2 51-75-2 4033
50
Benzocaine Approved Phase 3 1994-09-7, 94-09-7 2337

Interventional clinical trials:

(show top 50) (show all 95)
id Name Status NCT ID Phase
1 The Study of rHuTPO/rHuIL-11 in the Treatment for Chemotherapy-induced Thrombocytopenia in Patients With NSCLC Unknown status NCT02344979 Phase 4
2 A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia Completed NCT00220311 Phase 4
3 Safety of Orectalip® (Oxaliplatin) as Adjuvant Treatment for High-risk Stage-Ⅱ Colorectal Cancer Completed NCT02284529 Phase 4
4 Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients Recruiting NCT02267993 Phase 4
5 Caffeic Acid Combining High-dose Dexamethasone in Management of ITP Recruiting NCT02556814 Phase 4
6 Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP) Withdrawn NCT02642380 Phase 4
7 A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS) Completed NCT02158936 Phase 3
8 Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia Completed NCT02334813 Phase 3
9 Caffeic Acid Tablets as a Second-line Therapy for ITP Completed NCT02351622 Phase 3
10 A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer Completed NCT00001338 Phase 3
11 Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia Completed NCT00039910 Phase 3
12 Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia Completed NCT00037791 Phase 3
13 Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia Completed NCT00038311 Phase 3
14 Enoxaparin Low Molecular Weight Heparin (LMWH) in Advanced Non Small Cell Lung Cancer: Effect on Survival and Symptom Control in Patients Undergoing First Line Chemotherapy (SYRINGES) Completed NCT00771563 Phase 3
15 Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL Completed NCT01722487 Phase 3
16 Study of Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP Completed NCT00774202 Phase 2, Phase 3
17 Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00540514 Phase 3
18 The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Recruiting NCT01566695 Phase 3
19 Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML Recruiting NCT02214407 Phase 3
20 Clinical Trial on Ganoderma Spore Lipids Combined With Chemo in Patients With G.I. Cancers Recruiting NCT02785523 Phase 3
21 Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation Recruiting NCT00893399 Phase 3
22 Therapy of Adults Affected by Idiopathic Thrombocytopenic Purpura With Dexamethasone Recruiting NCT02914054 Phase 2, Phase 3
23 A Phase Ⅲ Study of Genetically Modified Recombinant Human Interleukin-11 Active, not recruiting NCT01663441 Phase 3
24 Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation Active, not recruiting NCT01237808 Phase 3
25 Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia Active, not recruiting NCT00824265 Phase 3
26 Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia Active, not recruiting NCT00748189 Phase 3
27 Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma Active, not recruiting NCT00567567 Phase 3
28 Clinical Trial on the Prevention of Thrombocytopenia After First-line Chemotherapy Terminated NCT01319669 Phase 2, Phase 3
29 Comparing Fresh Random Platelets and Autologous Cryopreserved Thrombosol Treated Autologous Platelets Terminated NCT00074763 Phase 3
30 Complementary Treatment of PG2 to Improve Clinical Benefit Response and Quality of Life in Fatigue Terminated NCT00518869 Phase 2, Phase 3
31 Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP) Terminated NCT00411801 Phase 3
32 A Multicentre Investigation of 2 Cycles Rituximab Compared With Standard Regimen in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia (ITP) Withdrawn NCT02137681 Phase 3
33 Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) Unknown status NCT00628238 Phase 2
34 Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine Unknown status NCT01180322 Phase 2
35 SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy Completed NCT00102726 Phase 2
36 A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma Completed NCT00283439 Phase 1, Phase 2
37 Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC) Completed NCT00413283 Phase 2
38 A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for Thrombocytopenia Completed NCT01488565 Phase 2
39 A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid Completed NCT00418665 Phase 2
40 A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2
41 Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)for the Treatment of Myelodysplastic Syndromes (MDS) Completed NCT00413114 Phase 2
42 Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Purpura (REPEAT) Completed NCT00424177 Phase 2
43 Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag Completed NCT01147809 Phase 2
44 Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents Completed NCT00321711 Phase 2
45 Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP) Completed NCT01279694 Phase 1, Phase 2
46 A Safety and Efficacy Study of Eltrombopag in Subjects With AML Completed NCT01890746 Phase 2
47 Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis Completed NCT00931762 Phase 2
48 AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin Completed NCT00147225 Phase 1, Phase 2
49 Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma Completed NCT00299182 Phase 1, Phase 2
50 A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia Completed NCT01263704 Phase 2

Search NIH Clinical Center for Cyclic Thrombocytopenia

Genetic Tests for Cyclic Thrombocytopenia

Anatomical Context for Cyclic Thrombocytopenia

MalaCards organs/tissues related to Cyclic Thrombocytopenia:

39
T Cells, Testes

Publications for Cyclic Thrombocytopenia

Articles related to Cyclic Thrombocytopenia:

(show all 38)
id Title Authors Year
1
Cyclic thrombocytopenia related to menstrual cycle: a case report and literature review. ( 25419404 )
2014
2
Cyclic thrombocytopenia associated with marked rebound thrombocytosis and fluctuating levels of endogenous thrombopoietin and reticulated platelets: a case report. ( 22038676 )
2012
3
Cyclic thrombocytopenia: A case report. ( 27263605 )
2010
4
Successful treatment of cyclic thrombocytopenia with thrombopoietin-mimetic agents: a report of two patients. ( 19484732 )
2009
5
Fluctuations in thrombopoietin, immature platelet fraction, and glycocalicin levels in a patient with cyclic thrombocytopenia. ( 19728020 )
2009
6
Molecular diagnosis of granulocytic anaplasmosis and infectious cyclic thrombocytopenia by PCR-RFLP. ( 17135540 )
2006
7
Investigation of persistent hypochromic microcytosis unmasks hemoglobin Evanston [alpha 14 (A12) Try--> Arg] in a patient of cyclic thrombocytopenia preceding Takayasu's disease. ( 16273737 )
2005
8
Human cyclic thrombocytopenia and Anaplasma spp. infection. ( 15654914 )
2005
9
Is complete remission of cyclic thrombocytopenia related to correction of cobalamin deficiency due to H. pylori eradication? ( 15650554 )
2005
10
Idiopathic cyclic thrombocytopenia. ( 15572217 )
2005
11
Large granular lymphocytic proliferation-associated cyclic thrombocytopenia. ( 16044437 )
2005
12
Complete remission of cyclic thrombocytopenia after Helicobacter pylori eradication. ( 15205594 )
2004
13
Cyclic thrombocytopenia and polycythemia vera. ( 12574969 )
2003
14
Clonal T cell-mediated cyclic thrombocytopenia. ( 12472588 )
2002
15
Effective treatment of cyclic thrombocytopenia with cepharanthin. ( 10530079 )
1999
16
Clinical manifestations of infectious canine cyclic thrombocytopenia. ( 9308149 )
1997
17
Cyclic thrombocytopenia in a patient treated with cyclosporine for refractory idiopathic thrombocytopenic purpura. ( 9395191 )
1997
18
Cyclic change of cytokines in a patient with cyclic thrombocytopenia. ( 8757531 )
1996
19
Serum thrombopoietin levels in cyclic thrombocytopenia. ( 8639873 )
1996
20
Canine infectious cyclic thrombocytopenia found in Taiwan. ( 8741613 )
1996
21
Synchronous fluctuation of interleukin-6 and platelet count in cyclic thrombocytopenia and thrombocytosis. ( 7496073 )
1995
22
Cyclic thrombocytopenia successfully treated with low dose hormonal contraception. ( 7832199 )
1995
23
Megakaryopoiesis in patients with cyclic thrombocytopenia. ( 7577630 )
1995
24
Cyclic thrombocytopenia associated with IgM anti-GPIIb-IIIa autoantibodies. ( 7529542 )
1994
25
A case of common variable immunodeficiency associated with cyclic thrombocytopenia. ( 7871984 )
1994
26
Acquired cyclic thrombocytopenia-thrombocytosis with periodic defect of platelet function. ( 7918035 )
1993
27
Periodic production of antiplatelet autoantibody directed against GPIIIa in cyclic thrombocytopenia. ( 8362605 )
1993
28
Cell-mediated cyclic thrombocytopenia treated with azathioprine. ( 2012761 )
1991
29
Danazol therapy for cyclic thrombocytopenia. ( 2012064 )
1991
30
Cyclic thrombocytopenia of apparent autoimmune etiology. ( 2713494 )
1989
31
Idiopathic cyclic thrombocytopenia of childhood. ( 2712241 )
1989
32
Menstrual cyclic thrombocytopenia. ( 2713272 )
1989
33
Serologic diagnosis of infectious cyclic thrombocytopenia in dogs using an indirect fluorescent antibody test. ( 6362502 )
1983
34
Cyclic thrombocytopenia induced by a Rickettsia-like agent in dogs. ( 627738 )
1978
35
Cyclic thrombocytopenia: a thrombopoietin deficiency? ( 4832304 )
1974
36
Cyclic thrombocytopenia. Case report and review of literature. ( 4598703 )
1974
37
Cyclic thrombocytopenia associated with multiple autoantibodies. ( 5797783 )
1969
38
Cyclic thrombocytopenia of acute type. ( 4295269 )
1967

Variations for Cyclic Thrombocytopenia

Expression for Cyclic Thrombocytopenia

Search GEO for disease gene expression data for Cyclic Thrombocytopenia.

Pathways for Cyclic Thrombocytopenia

Pathways related to Cyclic Thrombocytopenia according to GeneCards Suite gene sharing:

(show all 20)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.47 CSF2 IL11 IL3 IL7 KITLG THPO
2
Show member pathways
13.31 CSF2 IL11 IL3 IL7 KITLG THPO
3
Show member pathways
13.17 IL11 IL3 IL7 KITLG THPO
4
Show member pathways
13.1 CSF2 IL11 IL3 IL7 KITLG THPO
5
Show member pathways
13.02 CSF2 IL11 IL3 IL7 KITLG
6
Show member pathways
12.95 CSF2 GP1BA IL3 THPO
7
Show member pathways
12.91 CSF2 IL11 IL3 IL7 KITLG THPO
8
Show member pathways
12.36 IL3 KITLG THPO
9 12.27 IL3 IL7 KITLG
10
Show member pathways
11.89 CSF2 IL11 IL3 IL7 THPO
11 11.75 IL11 IL3 KITLG THPO
12 11.57 CSF2 GP1BA IL11 IL3 IL7 KITLG
13 11.55 CSF2 IL11
14
Show member pathways
11.46 CSF2 IL3
15 11.41 IL3 KITLG THPO
16 11.31 IL11 IL3 KITLG
17 11.29 CSF2 IL3 KITLG
18 11.15 CSF2 GP1BA IL11 IL3 IL7 KITLG
19 10.94 CSF2 IL11 IL3 IL7
20 10.93 CSF2 IL11 IL3 IL7

GO Terms for Cyclic Thrombocytopenia

Cellular components related to Cyclic Thrombocytopenia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.43 CSF2 IL11 IL3 IL7 KITLG THPO
2 extracellular space GO:0005615 9.1 CSF2 IL11 IL3 IL7 KITLG THPO

Biological processes related to Cyclic Thrombocytopenia according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.67 CSF2 IL3 IL7
2 cell-cell signaling GO:0007267 9.63 IL11 IL3 IL7
3 MAPK cascade GO:0000165 9.61 CSF2 IL3 KITLG
4 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.48 CSF2 IL3
5 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.43 IL11 IL3 KITLG
6 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.4 CSF2 IL7
7 positive regulation of tyrosine phosphorylation of Stat5 protein GO:0042523 9.37 CSF2 IL3
8 embryonic hemopoiesis GO:0035162 9.32 IL3 KITLG
9 positive regulation of hematopoietic stem cell proliferation GO:1902035 9.16 KITLG THPO
10 positive regulation of DNA replication GO:0045740 9.13 CSF2 IL3 KITLG
11 positive regulation of cell proliferation GO:0008284 9.02 CSF2 IL11 IL3 IL7 KITLG

Molecular functions related to Cyclic Thrombocytopenia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.43 CSF2 IL11 IL3 IL7 KITLG THPO
2 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.33 CSF2 IL3 KITLG
3 growth factor activity GO:0008083 9.1 CSF2 IL11 IL3 IL7 KITLG THPO

Sources for Cyclic Thrombocytopenia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....